← All trials
NCT05469659
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2021
- Primary completion
- Oct 30, 2025
- Completion date
- Oct 30, 2026
- First posted
- Jul 22, 2022
- Last posted
- Jul 22, 2022
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shinshu UniversityLead sponsor
- KowaCollaborator
- Shinshu UniversityReponsible party - principal investigator
- Shinshu UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.